Semaglutide weight loss results: what happens after you stop

What did @ginastone20 actually say?

Honestly? Not much, in terms of specifics. The entire transcript is a loop of one sentence: "the drugs are working." That's it. No dose mentioned, no timeline of use, no side effects, no mechanism explained. She stopped semaglutide three months ago and is grateful for the results, which she shared visually rather than verbally. The claim is simple and personal: she took semaglutide and it helped her lose weight.

That's a completely legitimate thing to share. It's also a claim so vague it's almost impossible to fact-check in detail. There's no pseudoscience here. There's no dosing advice, no comparison to brand-name versus compounded versions, and no promise that it will work for anyone else. She said the drug worked for her. That's the whole story.

Does the science back this up?

Yes, broadly. Semaglutide has some of the strongest weight-loss data of any pharmacological intervention studied in non-surgical populations. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that weekly subcutaneous semaglutide 2.4mg produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity, compared to 2.4% with placebo.

The mechanism is well-established. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves insulin sensitivity. These are not minor effects. Most participants in STEP trials reported meaningful reductions in hunger and food noise, which aligns with what many patients describe anecdotally as the drug "working."

So when @ginastone20 says the drugs worked, she is describing an outcome that clinical trials support happening in a significant percentage of users.

What did they get wrong (or right)?

She didn't get much wrong, because she barely said anything clinically specific. That's worth noting. A lot of GLP-1 content on TikTok is loaded with misinformation: incorrect dosing protocols, claims that compounded semaglutide is equivalent to Wegovy, or suggestions that these drugs are consequence-free. None of that appears here.

What she did get right, implicitly, is that semaglutide is a time-limited intervention for many people. She describes her journey as ended, which reflects real clinical reality. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) showed cardiovascular benefits during active treatment, but weight regain after stopping is a documented issue. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that one year after stopping semaglutide, participants regained about two-thirds of the weight they had lost.

She doesn't address that, but she doesn't pretend it won't happen either. The framing is grateful, not triumphal. That's a more honest emotional register than most weight-loss content on this platform.

What should you actually know?

Semaglutide works for a lot of people. It also stops working when you stop taking it, for most people. That's not a failure of the drug. It reflects that obesity is a chronic condition with biological drivers that don't disappear after a course of medication.

A few things the video doesn't tell you that matter. First, not everyone responds equally. The STEP 1 trial showed a wide range of outcomes, and roughly 10% of participants lost less than 5% of body weight. Second, side effects are real and underreported in success-story content. Nausea, vomiting, and gastrointestinal distress affected a majority of participants in clinical trials. Third, access and cost remain serious barriers. Wegovy listed at over $1,300 per month before insurance as of 2024.

If you are considering semaglutide, the conversation should happen with a licensed clinician who can review your metabolic health, contraindications (including personal or family history of medullary thyroid carcinoma), and realistic expectations about long-term maintenance.